Minerva Neurosciences Advances Roluperidone into Phase 3 Trial for Schizophrenia Negative Symptoms

Event summary

  • First patient screened in global Phase 3 trial for roluperidone, targeting negative symptoms of schizophrenia.
  • Trial will enroll 380 patients across 40 clinical sites in the US and Europe, with topline data expected in 2H 2027.
  • Roluperidone is the only late-stage drug candidate for this high-need population with no FDA-approved treatments.
  • Phase 3 trial follows positive results from prior Phase 2b and Phase 3 trials (C03 and C07) with the 64 mg dose.

The big picture

Minerva Neurosciences is advancing roluperidone into a pivotal Phase 3 trial, addressing a significant unmet need in schizophrenia treatment. The trial's success could position roluperidone as the first FDA-approved therapy for negative symptoms, a market with no current approved options. The biopharmaceutical company's progress reflects broader industry efforts to develop targeted treatments for complex CNS disorders, where innovation remains critical despite high development risks.

What we're watching

Execution Risk
Whether Minerva can maintain the consistency of prior trial results in this larger, global Phase 3 study.
Regulatory Pathway
How the FDA's feedback on trial design will influence the likelihood of approval for roluperidone.
Market Opportunity
The pace at which roluperidone could capture market share if approved, given the lack of FDA-approved treatments for negative symptoms of schizophrenia.

Related topics

Drug Development